Clinical Trials
13 trialsNCT05804669 2026-06-04
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Crinetics Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT03604198 2026-04-21
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Corcept Therapeutics
Phase 2 Active not recruiting
NCT05307328 2025-10-08
RESCUE
Sparrow Pharmaceuticals
Phase 2 Completed
NCT03697109 2025-07-16
GRACE
Corcept Therapeutics
Phase 3 Completed
NCT06576336 2024-08-28
3DAdrenal
University of Palermo
Phase 4 Completed
NCT04373265 2024-02-23
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Corcept Therapeutics
Phase 1 Completed
NCT05839483 2023-07-17
CXCR4 Targeted PET Imaging in APA Preoperative Localization Diagnosis
Zhongnan Hospital
Phase NA Unknown
NCT05361083 2022-05-04
First-in-human Evaluation of [18F]CETO
Uppsala University
Phase EARLY_PHASE1 Completed
NCT02804750 2019-10-15
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Corcept Therapeutics
Phase 2 Completed
NCT00958841 2016-07-26
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Novartis
Phase 2 Terminated
NCT00936741 2014-04-02
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Corcept Therapeutics
Phase 3 Completed
NCT01371565 2014-03-18
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Corcept Therapeutics
Phase 3 Completed
NCT00569582 2013-08-22
SEISMIC
Corcept Therapeutics
Phase 3 Completed